Get the Stockscreener App
2.37
5.80%
0.13
After Hours:
2.35
-0.02
-0.84%
Inflarx N V stock is traded at $2.37, with a volume of 221.04K.
It is up +5.80% in the last 24 hours and down -10.23% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$2.24
Open:
$2.2
24h Volume:
221.04K
Relative Volume:
0.80
Market Cap:
$139.55M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-2.7424
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
+0.00%
1M Performance:
-10.23%
6M Performance:
+52.90%
1Y Performance:
+43.64%
1-Day Range:
$2.20
$2.40
1-Week Range:
$2.16
$2.47
52-Week Range:
$1.165
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
2.37 | 139.55M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx (IFRX) Stock Sees After-Market Gains - Stocks Telegraph
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewswire
InflaRx to Present at Guggenheim SMID Cap Biotech Conference: Spotlight on Vilobelimab Pipeline - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 15.0% - MarketBeat
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug - MSN
InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN
InflaRx secures European Commission approval for ARDS drug - European Biotechnology News
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - MarketBeat
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS - Yahoo Finance
InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS - TipRanks
InflaRx Receives European Commission Approval for GOHIBIC® - GlobeNewswire
InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress - Seeking Alpha
InflaRx's GOHIBIC Makes History as First EU-Approved Treatment for COVID-19 ARDS - StockTitan
InflaRx Announces Participation in January Events in San Francisco - The Manila Times
InflaRx to Present at Major Biotech Events in San Francisco, Showcasing Novel Disease Response Solutions - StockTitan
InflaRx (NASDAQ:IFRX) Sees Large Growth in Short Interest - MarketBeat
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
US Penny Stocks To Watch In December 2024 - Simply Wall St
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy - Investing.com Nigeria
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy By Investing.com - Investing.com South Africa
InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug - TipRanks
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewswire
InflaRx Launches Phase 2a Trial for Billion-Dollar Skin Disease Drug INF904 - StockTitan
InflaRx (NASDAQ:IFRX) Trading 3.8% HigherHere's Why - MarketBeat
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com Canada
10 Best German Stocks To Buy Now - Insider Monkey
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Insider Monkey
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India
InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி
InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire
InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan
FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat
Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St
InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):